Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years-of therapy

Hepatology

Volumn 49, Issue 5, 2009, Pages 1503-1514

  Tenney, Daniel J ^a   Rose, Ronald E ^a   Baldick, Carl J ^a   Pokornowski, Kevin A ^a   Eggers, Betsy J ^a   Fang, Jie ^a   Wichroski, Michael J ^a   Xu, Dong ^a   Yang, Joanna ^a   Wilber, Richard B ^a   Colonno, Richard J ^a,b  

^a BRISTOL MYERS SQUIBB   (United States)

^b Presidio Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE; VIRUS DNA; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IN VITRO STUDY; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS GENOME; VIRUS ISOLATION; FOLLOW UP; GENETICS; HEALTH SURVEY; MULTIDRUG RESISTANCE; TIME;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; POPULATION SURVEILLANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 66149115173     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22841     Document Type: Article

References (38)

1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol Rev 2006;28:112-125.
2. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology 2008;134:405-415.
3. Lok A, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
4. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. HEPATOLOGY 2000;32:866-867.
5. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696.
6. Lai C-L, Gane E, Hsu C-W, Thongsawat S, Wang Y, Chen Y, et al. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. [Abstract] HEPATOLOGY 2006;44:222A.
7. Standring DN, Seifer M, Patty A, Chapron C, Van Doorn LJ, Chao G, et al. HBV resistance determination from the telbivudine globe registration trial. J Hepatol 2006;44:S191.
8. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507.
9. Delaney WE 4th. Progress in the treatment of chronic hepatitis B: longterm experience with adefovir dipivoxil. J Antimicrob Chemother 2007; 59:827-832.
10. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
11. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
12. Leung N, Peng C-Y, Sollano L, Leshmana L, Yuen M-F, Jeffers L et al. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive adults: 24 wk results (E.A.R.L.Y. Study). [Abstract] HEPATOLOGY 2006;44(4 Suppl. 1):554A.
13. Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008;48:895-902.
14. Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. HEPATOLOGY 2008;47:1473-1482.
15. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudinerefractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-911.
16. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. HEPATOLOGY 2006;44:1656-1665.
17. Yokosuka O, Kumada H, Toyota J, Takaguchi K, Kobashi H, Shindo M, et al. Three year assessment of entecavir (ETV) resistance in nucleosidenaive and lamivudine (LVD) refractory Japanese patients with chronic hepatitis B (CHB). Hepatol Int 2008;2:A161 (Abstract FP067).
18. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabino-furanosyluracil. Antimicrob Agents Chemother 2001;45:2495-2501.
19. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WEt. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625-633.
20. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001;75:4771-4779.
21. Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007;81:3992-4001.
22. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. HEPATOLOGY 2006;43:1385-1391.
23. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006;55:1488-1495.
24. Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005;43:937-943.
25. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008;48:747-755.
26. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-1209.
27. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for the treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049.
28. Colonno R, Rose R, Pokornowski K, Baldick C, Eggers B, Xu D, et al. Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients. [Abstract] J Hepatol 2007;46:s295.
29. Colonno R, Rose R, Pokornowski K, Baldick C, Klesczewski K, Tenney D. Assessment at three years shows high barrier to resistance is maintained in entecavir treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. [Abstract]HEPATOLOGY 2006;44:229A.
30. Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006;50:3867-3874.
31. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: Can we prevent this monster from growing? J Viral Hepat 2007;14(Suppl 1):29-36.
32. Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007;39:149-152.
33. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007;46:531-538.
34. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. HEPATOLOGY 2006;44:703-712.
35. Tenney DJ, Baldick CJ, Rose RE, Mazzucco CE, Eggers BJ, Pokornowski KA, et al. Only a subset of HBV substitutions at entecavir resistance residues lead to phenotypic resistance and virologic rebound. HEPATOLOGY 2006;44(4 Suppl. 1):253A-254A.
36. Qi X, Xiong S, Yang H, Miller M, Delaney WI. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antiviral Ther 2007;12:355-362.
37. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. HEPATOLOGY 2005;41:1391-1398.
38. Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, et al. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 2007;51:2240-2243.